Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

NCT03824795 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

DRUG: MGB-BP-3

Sponsor

MGB Biopharma Limited

Collaborators

[object Object]